<p>All drugs were incubated for 24 hr. Values are means±S.E.M. of 5 replicas. <b>*, <sup>+</sup>, <sup>#</sup></b>, <sup>π</sup>, <sup>$</sup> and <sup>%</sup> denote significant difference (P<0.05) vs. control, cisplatin, cisplatin+pioglitazone, cisplatin+fenofibrate cisplatin+pioglitazone+fenofibrate and cisplatin+thalidomide values, respectively.</p
<p>(A-B) MTT assay on proliferating A1 cells treated with increasing concentrations of temozolomide ...
<p>Immunoblot analyses showing expression levels of phospho-p38, p38, phospho-ERK1/2, ERK1/2, phosph...
<p>A) The percentage of apoptotic TECs after incubation with 5 µg/ml of cisplatin was evaluated by t...
<p>All drugs were administered 2 days before cisplatin injection and continued for 3 days thereafter...
<p>All drugs were administered 2 days before cisplatin and continued for 3 days thereafter. Values a...
<p>(A) KYSE140 cells were treated with 10 µM cisplatin for 6, 12, or 24 h, and the RIPK3 mRNA level ...
Nephrotoxicity is a major side effect for the antineoplastic drug cisplatin. Here, we employed pharm...
<p>All drugs were administered 2 days before cisplatin injection and continued for 3 days thereafter...
<p>(A) Expression levels of cleaved PARP, an apoptotic marker, as measured by western blot for cells...
<p>IC30, 30% inhibitory concentration of cisplatin; IC50, 50% inhibitory concentration of cisplatin;...
<p>A) Colony assay. The indicated cell lines were treated with ½ of the IC<sub>50</sub> dose of AZD2...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>(A) Western blot analysis indicated increased levels of p53 and phospho-p53 after 6 and 24 h of c...
<p><b><i>A–D:</i></b> Paraffin-embedded UM-SCC-74A tumor samples were stained for pSTAT3 (Y705) and ...
<p>(A) Effects of RIPK3 knockdown were determined using western blot analysis, β-Actin as a loading ...
<p>(A-B) MTT assay on proliferating A1 cells treated with increasing concentrations of temozolomide ...
<p>Immunoblot analyses showing expression levels of phospho-p38, p38, phospho-ERK1/2, ERK1/2, phosph...
<p>A) The percentage of apoptotic TECs after incubation with 5 µg/ml of cisplatin was evaluated by t...
<p>All drugs were administered 2 days before cisplatin injection and continued for 3 days thereafter...
<p>All drugs were administered 2 days before cisplatin and continued for 3 days thereafter. Values a...
<p>(A) KYSE140 cells were treated with 10 µM cisplatin for 6, 12, or 24 h, and the RIPK3 mRNA level ...
Nephrotoxicity is a major side effect for the antineoplastic drug cisplatin. Here, we employed pharm...
<p>All drugs were administered 2 days before cisplatin injection and continued for 3 days thereafter...
<p>(A) Expression levels of cleaved PARP, an apoptotic marker, as measured by western blot for cells...
<p>IC30, 30% inhibitory concentration of cisplatin; IC50, 50% inhibitory concentration of cisplatin;...
<p>A) Colony assay. The indicated cell lines were treated with ½ of the IC<sub>50</sub> dose of AZD2...
<p>QBC939 and HepG2 cells were treated with cisplatin for 12 or 24 h, and then cell viability, apopt...
<p>(A) Western blot analysis indicated increased levels of p53 and phospho-p53 after 6 and 24 h of c...
<p><b><i>A–D:</i></b> Paraffin-embedded UM-SCC-74A tumor samples were stained for pSTAT3 (Y705) and ...
<p>(A) Effects of RIPK3 knockdown were determined using western blot analysis, β-Actin as a loading ...
<p>(A-B) MTT assay on proliferating A1 cells treated with increasing concentrations of temozolomide ...
<p>Immunoblot analyses showing expression levels of phospho-p38, p38, phospho-ERK1/2, ERK1/2, phosph...
<p>A) The percentage of apoptotic TECs after incubation with 5 µg/ml of cisplatin was evaluated by t...